Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 12/20 | 0.59 |
| ▸ | SELP | P16109 | 8/20 | 0.50 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.48 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8515435 | 0.91 | SELE (0.55) | SELESELPLGALS9LGALS1LGALS3 | |
| SCHEMBL14823281 | 0.91 | SELE (0.55) | SELESELPLGALS9LGALS1LGALS3 | |
| SCHEMBL8514368 | 0.91 | SELE (0.55) | SELESELPLGALS9LGALS1LGALS3 | |
| SCHEMBL8514365 | 0.91 | SELE (0.55) | SELESELPLGALS9LGALS1LGALS3 | |
| SCHEMBL8515429 | 0.88 | SELE (0.56) | SELESELPLGALS9LGALS1LGALS3 | |
| SCHEMBL13077057 | 0.86 | SELE (0.57) | SELESELPLGALS9LGALS1LGALS3 | |
| SCHEMBL8515431 | 0.84 | SELE (0.62) | SELESELPLGALS9LGALS1LGALS3 | |
| SCHEMBL11981958 | 0.82 | SELE (0.79) | SELESELP | |
| SCHEMBL12309895 | 0.81 | SELE (0.71) | SELESELP | |
| SCHEMBL2003434 | 0.80 | SELE (0.91) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039442-B2 | Compounds and methods for treatment of sickle cell disease or complications associated therewith | GLYCOMIMETICS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090023679-A1 | Compounds and methods for treatment of sickle cell disease or complications associated therewith | GLYCOMIMETICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023679-A1 | Compounds and methods for treatment of sickle cell disease or complications associated therewith | HBG1, HBG2, SORD | SELE 8/4885SELP 55/4885LGALS9 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.